UY27078A1 - Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimentos para su preparación - Google Patents

Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimentos para su preparación

Info

Publication number
UY27078A1
UY27078A1 UY27078A UY27078A UY27078A1 UY 27078 A1 UY27078 A1 UY 27078A1 UY 27078 A UY27078 A UY 27078A UY 27078 A UY27078 A UY 27078A UY 27078 A1 UY27078 A1 UY 27078A1
Authority
UY
Uruguay
Prior art keywords
preparation
quinazoline
derivatives
employment
procedures
Prior art date
Application number
UY27078A
Other languages
English (en)
Inventor
Frank Himmelsbach
Elke Langkopf
Stefan Blech
Birgit Jung
Anke Baum
Flavio Solca
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27078A1 publication Critical patent/UY27078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a derivados de quinazolina de la fórmula general (I) en la que Ra, Rb y Rc están definidos como en la reivindicación 1, a sus tautómeros, sus estereoisómeros y sus sales, en particular sus sales fisiológicamente compatibles con ácidos o bases inorgánicas u orgánicos, que presentan valiosas propiedades farmacológicas, en particular un efecto inhibidor sobre la transducción de senales inducidas por tirosina-quinasa, a su empleo para el tratamiento de enfermedades, en particular de enfermedades tumorales, de enfermedades de los pulmones y de las vías respiratorias, y a su preparación.
UY27078A 2000-12-20 2001-12-17 Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimentos para su preparación UY27078A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (de) 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
UY27078A1 true UY27078A1 (es) 2002-07-31

Family

ID=7667887

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27078A UY27078A1 (es) 2000-12-20 2001-12-17 Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimentos para su preparación

Country Status (40)

Country Link
EP (2) EP1345910B9 (es)
JP (1) JP3827641B2 (es)
KR (1) KR100852102B1 (es)
CN (1) CN1277822C (es)
AR (1) AR040524A1 (es)
AT (1) ATE430136T1 (es)
AU (2) AU2002219174B2 (es)
BE (1) BE2014C009I2 (es)
BG (1) BG66139B1 (es)
BR (1) BRPI0116266B8 (es)
CA (1) CA2432428C (es)
CY (2) CY1109290T1 (es)
CZ (1) CZ302721B6 (es)
DE (2) DE10063435A1 (es)
DK (1) DK1345910T3 (es)
EA (1) EA006317B1 (es)
EE (1) EE05244B1 (es)
ES (1) ES2326617T3 (es)
FR (1) FR14C0009I2 (es)
HK (1) HK1060571A1 (es)
HR (1) HRP20030504B1 (es)
HU (2) HU228874B1 (es)
IL (2) IL156277A0 (es)
LT (1) LTC1345910I2 (es)
LU (1) LU92370I2 (es)
ME (1) ME02777B (es)
MX (1) MXPA03005559A (es)
MY (1) MY136086A (es)
NO (3) NO325672B1 (es)
NZ (1) NZ526918A (es)
PL (1) PL214798B1 (es)
PT (1) PT1345910E (es)
RS (1) RS50860B (es)
SI (1) SI1345910T1 (es)
SK (1) SK287573B6 (es)
TW (1) TWI295992B (es)
UA (1) UA74614C2 (es)
UY (1) UY27078A1 (es)
WO (1) WO2002050043A1 (es)
ZA (1) ZA200304141B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71976C2 (en) 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
DE10307165A1 (de) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
UA85706C2 (en) * 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006081741A1 (fr) * 2005-02-05 2006-08-10 Piaoyang Sun Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
DK1948180T3 (da) 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
EP3173084B1 (en) * 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
US7960546B2 (en) * 2006-01-26 2011-06-14 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
ES2385613T3 (es) * 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
JP2012515184A (ja) 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
WO2010130757A1 (en) 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
WO2010130758A1 (en) * 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
US8735409B2 (en) * 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2608792B1 (en) 2010-08-26 2017-10-11 Boehringer Ingelheim International GmbH Methods of administering an egfr inhibitor
EP2643314B1 (en) * 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
KR20200003933A (ko) 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
EP2753616A1 (en) 2011-10-06 2014-07-16 Ratiopharm GmbH Crystalline forms of afatinib di-maleate
CN103073539B (zh) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
CN104080774B (zh) 2012-01-17 2017-02-22 安斯泰来制药株式会社 吡嗪甲酰胺化合物
CN103772380A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US20150368230A1 (en) 2013-02-01 2015-12-24 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (sl) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
WO2014180271A1 (zh) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103254182A (zh) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 一种阿法替尼的制备方法
WO2014183560A1 (zh) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103242303B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN103755688B (zh) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 一种阿法替尼化合物的制备方法
US9242965B2 (en) * 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EA031059B1 (ru) 2014-01-02 2018-11-30 Тева Фармасьютикалз Интернэшнл Гмбх Кристаллическая форма альфа дималеата афатиниба
CN105315263B (zh) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 阿法替尼中间体的合成方法
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (zh) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
US10231973B2 (en) 2015-03-20 2019-03-19 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of quinazoline derivative and method for preparing the same
CN105175400B (zh) * 2015-09-29 2018-04-10 河北神威药业有限公司 一种阿法替尼中间体的制备方法
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (zh) * 2016-10-21 2019-05-24 河北神威药业有限公司 一种制备阿法替尼的中间体及其对映异构体的检测方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JP2021506974A (ja) * 2017-12-18 2021-02-22 スターングリーン、インク． チロシンキナーゼ阻害剤として有用なピリミジン化合物
CN110437163A (zh) * 2018-05-03 2019-11-12 斯特恩格林公司 作为酪氨酸激酶抑制剂的嘧啶类化合物
CN113382986A (zh) 2018-09-25 2021-09-10 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
CN109265449B (zh) * 2018-11-07 2021-11-23 沈阳工业大学 Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109824657A (zh) * 2019-03-26 2019-05-31 石药集团中奇制药技术（石家庄）有限公司 一种二马来酸阿法替尼新晶型及其制备方法和应用
CN110590682A (zh) * 2019-10-14 2019-12-20 重庆医科大学 一种制备阿法替尼杂质的方法以及制备的杂质
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TWI847289B (zh) * 2021-09-30 2024-07-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、組合物及其應用
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126351A0 (en) * 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DE19911366A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19908567A1 (de) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU3281600A (en) * 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
UA71976C2 (en) * 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
ES2280375T3 (es) * 2000-04-08 2007-09-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Heterociclos biciclicos, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparacion.

Also Published As

Publication number Publication date
EP1345910A1 (de) 2003-09-24
EE200300300A (et) 2003-10-15
CN1481370A (zh) 2004-03-10
CY1109290T1 (el) 2014-07-02
HRP20030504B1 (en) 2011-09-30
PL214798B1 (pl) 2013-09-30
HUP0301852A2 (hu) 2003-09-29
EP1345910B1 (de) 2009-04-29
DE50114874D1 (de) 2009-06-10
AU1917402A (en) 2002-07-01
UA74614C2 (en) 2006-01-16
ME02777B (me) 2011-10-10
NO20032726D0 (no) 2003-06-16
NO2014003I2 (no) 2015-10-19
MY136086A (en) 2008-08-29
NO2014003I1 (no) 2014-06-02
HK1060571A1 (en) 2004-08-13
EA200300671A1 (ru) 2004-06-24
HUS1400005I1 (hu) 2017-08-28
NO325672B1 (no) 2008-07-07
EP1345910B9 (de) 2014-06-04
MEP59508A (en) 2011-05-10
HUP0301852A3 (en) 2008-03-28
EA006317B1 (ru) 2005-10-27
AR040524A1 (es) 2005-04-13
LU92370I2 (fr) 2014-03-31
CN1277822C (zh) 2006-10-04
BG66139B1 (bg) 2011-07-29
TWI295992B (en) 2008-04-21
YU49603A (sh) 2006-05-25
KR20030071787A (ko) 2003-09-06
ATE430136T1 (de) 2009-05-15
BE2014C009I2 (es) 2021-02-04
PL361798A1 (en) 2004-10-04
AU2002219174B2 (en) 2007-09-06
EP2112140A1 (de) 2009-10-28
CZ20031930A3 (cs) 2003-10-15
HRP20030504A2 (en) 2005-06-30
LU92370I9 (es) 2019-01-17
KR100852102B1 (ko) 2008-08-13
CA2432428A1 (en) 2002-06-27
DK1345910T3 (da) 2009-07-20
EE05244B1 (et) 2009-12-15
MXPA03005559A (es) 2004-10-14
CA2432428C (en) 2009-09-01
ZA200304141B (en) 2004-04-15
RS50860B (sr) 2010-08-31
SK7712003A3 (en) 2003-10-07
ES2326617T9 (es) 2014-09-10
CY2014008I2 (el) 2015-12-09
IL156277A (en) 2009-12-24
FR14C0009I1 (fr) 2014-03-07
LTPA2014005I1 (lt) 2022-05-25
PT1345910E (pt) 2009-07-14
HU228874B1 (en) 2013-06-28
NO20032726L (no) 2003-06-16
DE10063435A1 (de) 2002-07-04
CY2014008I1 (el) 2014-07-02
JP2004516283A (ja) 2004-06-03
BG107929A (bg) 2005-01-31
WO2002050043A1 (de) 2002-06-27
SI1345910T1 (sl) 2009-08-31
NZ526918A (en) 2006-11-30
FR14C0009I2 (fr) 2014-11-14
BR0116266A (pt) 2004-02-17
SK287573B6 (sk) 2011-03-04
LTC1345910I2 (lt) 2022-06-10
ES2326617T3 (es) 2009-10-16
BRPI0116266B8 (pt) 2021-07-27
CZ302721B6 (cs) 2011-09-21
BRPI0116266B1 (pt) 2017-10-31
JP3827641B2 (ja) 2006-09-27
IL156277A0 (en) 2004-01-04
NO2022028I1 (no) 2022-07-01

Similar Documents

Publication Publication Date Title
UY27078A1 (es) Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimentos para su preparación
ECSP034646A (es) Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion
UY26903A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación
UY26659A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación
UY27737A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación.
AR009937A1 (es) Pirimido [5,4-d] pirimidinas, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparacion
UY26902A1 (es) Heterocíclicos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación
UY28191A1 (es) Heterociclos biciclicos, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación.
UY27767A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su empleo, y procedimientos para su preparación.
UY26513A1 (es) Nuevas piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimiento para su preparación.
AR006108A1 (es) Pirimido[5,4-d]pirimidinas, sus sales fisiologicamente compatibles, un procedimiento para su preparacion, su empleo para la preparacion de composiciones farmaceuticas, y las composiciones farmaceuticas que las contienen
YU90901A (sh) Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje
EE9700211A (et) Pürimido[5,4-d]pürimidiinid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
EA201001241A1 (ru) Спирогетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
AR006569A1 (es) Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion
AR058286A1 (es) Heterociclos biciclicos derivados de quinazolina 4-amino sustituidas, medicamentos que contienen estos compuestos, su utilizacion en el tratamiento de enfermedades mediadas por la actividad de las tirosinquinasas y las tiroquinasas y procedimientos para su preparacion
UY26067A1 (es) Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimiento
ECSP099562A (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación
UY28347A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación
ECSP045330A (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimiento para su preparación
UY26492A1 (es) Bencimidazoles, su preparación y su empleo como medicamentos.
UY26905A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación
UY32855A (es) Heterocíclicos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20151021